Cardiac resynchronization therapy in patients with chronic heart failure is associated with anti-inflammatory and anti-remodeling effects

Clinical Biochemistry

Volumn 46, Issue 3, 2013, Pages 230-234

  Stanciu, Adina Elena ^a   Vatasescu, Radu Gabriel ^b   Stanciu, Marcel Marian ^c   Iorgulescu, Corneliu ^b   Vasile, Alexandra Ioana ^b   Dorobantu, Maria ^b  

^a Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^b Clinic Emergency Hospital Bucharest   (Romania)

^c UNIVERSITY POLITEHNICA OF BUCHAREST   (Romania)

Author keywords

Cardiac resynchronization therapy; Chronic heart failure; Extracellular matrix remodeling; Inflammation; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GELATINASE A; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEFIBRILLATOR; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HUMAN; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; VENTRICULAR PACEMAKER;

AGED; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; CASE-CONTROL STUDIES; CHRONIC DISEASE; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84871989405     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.11.002     Document Type: Article

References (26)

1. Hessel M.H.M., Bleeker G.B., Jeroen J., Henneman M.M., den Adel B., Klok M., et al. Reverse ventricular remodeling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur J Heart Fail 2007, 9:1058-1063.
2. Rahmouni H.W., Kirkpatrick J.N., St John Sutton M.G. Effects of cardiac resynchronization therapy on ventricular remodeling. Curr Heart Fail Rep 2008, 5:25-30.
3. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000, 35:569-582.
4. Takano H., Hasegawa H., Nagai T., Komuro I. Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies. Intern Med 2003, 42:465-469.
5. Long C.S. The role of interleukin-1 in the failing heart. Heart Fail Rev 2001, 6:81-94.
6. Fruhwald F.M., Fahrleitner-Pammer A., Berger R., Levya F., Freemantle N., Erdmann E., et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 2007, 28:1592-1597.
7. van Kimmenade R.R.J., Januzzi J.L. Emerging biomarkers in heart failure. Clin Chem 2012, 58:127-138.
8. Mitchell M.D., Laird R.E., Brown R.D., Long C.S. IL-1 stimulates rat cardiac fibroblast migration via MAP kinase pathways. Am J Physiol Heart Circ Physiol 2007, 292:1139-1147.
9. George J., Patal S., Wexler D., Roth A., Sheps D., Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005, 150:484-487.
10. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69:562-573.
11. Monahan K.M. Cardiac resynchronization therapy. Circulation 2008, 117:e192-e193.
12. Vidal B., Sitges M., Marigliano A., Diaz-Infante E., Azqueta M., Tamborero D., et al. Relation of response to cardiac resynchronization therapy to left ventricular reverse remodeling. Am J Cardiol 2006, 97:876-881.
13. Lecoq G., Leclercq C., Leray E., Crocq C., Alonso C., de Place C., et al. Clinical and electrocardiographic predictors of a positive response to cardiac resynchronization therapy in advance heart failure. Eur Heart J 2005, 26:1094-1100.
14. Mueller T., Gegenhuber A., Poelz W., Holtmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem 2003, 49:976-979.
15. Sanchez-Lazaro I.J., Almenar L., Reganon E., Vila V., Martínez-Dolz L., Martinez-Sales V., et al. Inflammatory markers in stable heart failure and their relationship with functional class. Int J Cardiol 2008, 129:388-393.
16. Corson M.A. Emerging inflammatory markers for assessing coronary heart disease risk. Curr Cardiol Rep 2009, 11:452-459.
17. Tsuruda T., Boerrigter G., Huntley B.K., Noser J.A., Cataliotti A., Costello-Boerrigter L.C., et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002, 91:1127-1134.
18. Groenning B.A., Nilsson J.C., Sondergaard L., Kjaer A., Larsson H.B.W., Hildebrandt P.R., et al. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail 2001, 3:699-708.
19. Groenning B.A., Nilsson J.C., Sondergaard L., Pedersen F., Trawinski J., Baumann M., et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J 2002, 143:923-929.
20. Hammerer-Lercher A., Neubauer E., Muller S., Pachinger O., Puschendorf B., Mair J., et al. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001, 310:193-197.
21. Hammerer-Lercher A., Ludwig W., Falkensammer G., Muller S., Neubauer E., Puschendorf B., et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem 2004, 50:1174-1183.
22. Spinale F.G. Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res 2002, 90:520-530.
23. Polyakova V., Hein S., Kostin S., Ziegelhoeffer T., Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004, 44:1609-1618.
24. Teodorakis G.N., Flevari P., Kroupis C., Adamopoulos S., Livanis E.G., Kostopoulou A., et al. Antiinflammatory effects of cardiac resynchronization therapy in patients with chronic heart failure. Pacing Clin Electrophysiol 2006, 29:255-261.
25. Tarquini R., Guerra C.T., Porciani M.C., Michelucci A., Padeletti M., Ricciardi G., et al. Effects of cardiac resynchronization therapy on systemic inflammation and neurohormonal pathways in heart failure. Cardiol J 2009, 16:545-552.
26. Tolosana J.M., Mont L., Sitges M., Berruezo A., Delgado V., Vidal B., et al. Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy. Eur J Heart Fail 2010, 12:492-498.